• Rewinding age in the eye: Life Biosciences plans the first human trial of ER‑100, using Oct‑4, Sox‑2 and Klf‑4 to reset epigenetic age . It targets glaucoma and optic‑nerve strokes and has a doxycycline on‑off switch

• Tiny sample, big insight: Osaka University’s AI model infers biological age from five drops of blood by analyzing 22 steroid hormones . Doubling cortisol raised biological age by ~1.5×

• Algorithms meet appetite: NIH’s Nutrition for Precision Health study is enrolling volunteers to learn how genes, proteins, metabolism and the microbiome influence responses to diets. It uses AI to predict individual reactions to foods and tailor meal plans.

• AI labs on warp speed: At Harvard, K‑Dense Beta sifted through 600k RNA profiles, identified 5k aging genes and built an aging clock in weeks , showing how AI can compress research timelines.

• Zombie cell cleanup: In head‑and‑neck cancer, the senolytics dasatinib and quercetin combined with PD‑1 immunotherapy boosted tumour responses and restored naïve T cells with fewer side effects

• Clocking the brain’s age: A machine‑learning “aging clock” assessed the biological age of brain cells and screened thousands of compounds . Three of the 453 hits improved memory in old mice and shifted gene expression toward youth

• Mood modulation via ultrasound: A UK trial is implanting a device that reads brain activity and sends ultrasound pulses to adjust neural circuits . About 30 patients with depression or addiction will test this less‑invasive brain‑computer interface

• Neuralink’s human leap: First implant recipient Noland Arbaugh now types and studies with his mind, and Elon Musk says recipients may soon beat anyone at reaction‑time games . By late 2025, 12 participants had logged more than 15k hours and the implant gained FDA Breakthrough status for speech restoration

• Gene editing gets personal: After the EU approved Casgevy in 2024, roughly 250 gene‑editing trials were active by early 2025 . Prime editing refines CRISPR’s precision , and researchers delivered bespoke CRISPR therapy via nanoparticles to a baby and revived a lost uricase pathway in lab liver cells

• Targeting the right zombies: A 2025 study showed that senescent cells arrested late in the cell cycle are more inflammatory and more responsive to senolytic drugs . Tailoring therapies to these subtypes could make senolytics safer .